Intech Investment Management LLC Grows Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Intech Investment Management LLC grew its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) by 176.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,631 shares of the company’s stock after acquiring an additional 33,567 shares during the period. Intech Investment Management LLC’s holdings in Applied Therapeutics were worth $45,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in Applied Therapeutics by 165.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 735,217 shares of the company’s stock valued at $6,249,000 after purchasing an additional 457,940 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Applied Therapeutics by 236.0% in the third quarter. The Manufacturers Life Insurance Company now owns 123,725 shares of the company’s stock valued at $1,052,000 after buying an additional 86,901 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Applied Therapeutics by 1,855.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 135,272 shares of the company’s stock valued at $1,150,000 after buying an additional 128,353 shares during the period. MetLife Investment Management LLC lifted its position in Applied Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 56,302 shares of the company’s stock worth $479,000 after acquiring an additional 31,724 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Applied Therapeutics by 37.8% in the 3rd quarter. Janus Henderson Group PLC now owns 10,541,528 shares of the company’s stock worth $89,656,000 after acquiring an additional 2,893,323 shares during the period. Institutional investors and hedge funds own 98.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on APLT. UBS Group reiterated a “neutral” rating and set a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Citigroup cut their price objective on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 29th. William Blair downgraded Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Robert W. Baird dropped their target price on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, November 29th. Finally, Royal Bank of Canada lowered their price objective on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a research note on Friday, December 20th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Stock Performance

NASDAQ APLT opened at $0.52 on Friday. Applied Therapeutics, Inc. has a one year low of $0.43 and a one year high of $10.62. The company has a 50-day simple moving average of $0.56 and a 200-day simple moving average of $3.82. The firm has a market capitalization of $60.07 million, a PE ratio of -0.32 and a beta of 1.88.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.